HIV Vaccine

An HIV vaccine is imperative for an enduring end to the epidemic.

An effective preventive HIV vaccine would teach the body how to prevent HIV infection. Vaccines are the most powerful public health tool—and an HIV vaccine would play an essential role in ensuring the end to the AIDS epidemic.

While effective vaccines remain years away, there are more reasons for hope than ever before. HIV vaccine research is more productive than ever, with multiple large-scale vaccine trials underway and dozens of vaccine approaches in development.

What We're Reading

First COVID, Now HIV. Moderna and San Diego Researchers Race To Make a Vaccine

Researchers plan to use a series of shots to teach people’s immune systems to produce powerful antibody responses against the virus. But while the strategy is raising hopes and is built on years of research, there’s no guarantee it succeeds.

October 7, 2021

HIV Vaccine

San Diego Union-Tribune

Will the Moderna HIV Vaccine Trials Succeed?

On August 11, Moderna, the biotech company behind one of the COVID-19 vaccines, posted a study record announcing that they were set to start Phase 1 of human trials on a HIV mRNA vaccine. These trials will consist of 56 adults between the ages of 18 to 50 years old who don't have HIV and test for safety, immune responses and antibodies.

September 1, 2021

HIV Vaccine

Paper

Featured Resources

HIV Vaccine Research: Building on the Lessons from COVID

Building on the lessons of COVID, HIV vaccine advocates can mobilize for an HIV vaccine research and access agenda. This two-page document gives suggested messaging.

May 2021

AVAC

HIV Vaccine

By The Numbers